LAVAL, QC and CAMBRIDGE, England, May 23, 2022 /PRNewswire/ Liminal BioSciences Inc. (NASDAQ: LMNL) ("Liminal BioSciences" or the "Company"), today announced that the first subject has been
Relief Therapeutics Holding SA / Key word(s): Study results Acer Therapeutics and Relief Therapeutics Announce Presentation of ACER-001 Data at the Genetic Metabolic Dieticians International Conference
Relief Therapeutics Holding SA / Key word(s): Study results12-Apr-2022 / 07:00 CET/CESTRelease of an ad hoc announcement pursuant to Art. 53 LRThe issuer is solely responsible for the content of this announcement.Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss ExchangeAcer Therapeutics and Relief Therape.